A service of StreetInsider.com
Welcome

Most Popular

AAPL 80.49
GOOG 259.56
RIMM 41.52
MSFT 17.53
C 4.71

Recently Added

HSE 0.00
MENT 5.65
SNPS 14.59
VIRL 3.42
GMBXF 0.57

Gaining Speed

BBDA 0.00
TIF 17.86
ESYM 0.00
DLTR 34.18
LDSR 0.00
6.20 +0.00 (0.00%) SCR

Click Here to Receive Instant E-mail and RSS Alerts

Stock Details

Last Trade:6.20 Change:+0.00 (0.00%) Prev Close:6.20 Open: 6.50 Days Range:6.07 – 6.53 52 Week Range: 4.41 - 15.88 Volume:66671 P/E: N/A
EPS:0.00

Recent Blog Posts

Blog Posts on 09/04/08 at 1:50am
Simcere Shows Positive Data from Cancer Drug Trial
Blog Posts on 08/12/08 at 7:23am
Top Pre-Market Analyst Upgrades (ALK, AMR, AAPL, CAL, DAL, DELL, JPM, LDK, PENN, SCR, SNSS, LCC)
Blog Posts on 08/08/08 at 5:22am
Six Key Chinese Healthcare ADRs
Blog Posts on 08/06/08 at 3:51pm
China ADRs: Mixed July
Blog Posts on 08/05/08 at 6:13am
Global Investing, BRIC by BRIC: Part II
Blog Posts on 05/19/08 at 6:38am
China Biopharma Growth Metrics
Blog Posts on 05/15/08 at 2:03am
Simcere Granted SFDA Approval for Generic Antibiotic
Blog Posts on 05/11/08 at 2:30am
China Biopharma: What’s Not to Like?
Blog Posts on 05/07/08 at 3:57am
Simcere’s Q1: Revenue Increases 26%
Blog Posts on 04/28/08 at 9:16am
Biotech in Review: Investments in China Drug Development
Blog Posts on 04/23/08 at 4:11am
Simcere Buys Cancer Drug Company
Blog Posts on 03/05/08 at 4:55am
Simcere Books Solid 2007
Blog Posts on 03/05/08 at 4:34am
Simcere Pharmaceutical Gains on Strong Earnings
Blog Posts on 11/27/07 at 2:58am
Simcere Acquires New Cancer Drug; Misses on Q3 Revenue
Blog Posts on 11/06/07 at 7:05am
Simcere Reports Unimpressive Q3 Results
Blog Posts on 10/15/07 at 8:29am
Simcere Invests Heavily in Rival Boda
Blog Posts on 09/16/07 at 10:09am
Recently Listed Simcere, Tongjitang Appear Attractively Priced
Blog Posts on 08/08/07 at 7:32am
Post IPO: Simcere Announces Q2 Earnings, and Posts Higher Revenues